A patient is vaccinated with Montanide ISA51-adjuvanted WT1 Trio cancer vaccine consisting of two WT1 CTL peptides (WT1-126 and WT1-235) and one WT1 HTL peptide (WT1-332) (2mg each) seven times at the
Sponsors
Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy, Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy
Conditions
Thymic cancer Thymoma Soft tissue sarcoma Malignant glioma Salivary gland cancer Head and neck mucoepidermoid carcinoma Olfactory neuroblastoma Head and neck mucosal malignant melanoma Ophthalmic malignant melanoma Cancer of the external auditory canal Testicular cancer Cancer of penis Adrenal cancer Malignant mesothelioma Cancer of the small intestine Merkel cell carcinoma Cutaneous lymphoma (Rare cancers listed above)Thymic cancer Thymoma Soft tissue sarcoma Malignant glioma Salivary gland cancer Head and neck mucoepidermoid carcinoma Olfactory neuroblastoma Head and neck mucosal malignant melanoma Ophthalmic malignant melanoma Cancer of the external auditory canal Testicular cancer Cancer of penis Adrenal cancer Malignant mesothelioma Cancer of the small intestine Merkel cell carcinoma Cutaneous lymphoma (Rare cancers listed above)
Unknown Phase
Long-term maintenance of anti-tumor immune responses by vaccination with tri-WT1 peptide cancer vaccine WT1 Trio
Active, not recruitingJPRN-UMIN000023578
Start: 2016-10-01Target: 90Updated: 2026-06-29
WT1 Trio Peptide-vaccine for Rare Cancers
Active, not recruitingJPRN-UMIN000023579
Start: 2017-03-31Target: 90Updated: 2026-06-29